Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

Por Gupta, Neeraj, Zhao, Yuan, Hui, Ai-Min, Esseltine, Dixie-Lee, Venkatakrishnan, Karthik
Publicado no Br J Clin Pharmacol (2015)

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials

Por Robinson, Don, Esseltine, Dixie‐Lee, Regnault, Antoine, Meunier, Juliette, Liu, Kevin, van de Velde, Helgi
Publicado no Br J Haematol (2016)

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

Por Moreau, Philippe, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, Rekhtman, Grigoriy, Masliak, Zvenyslava, Robak, Pawel, Esseltine, Dixie-Lee, Feng, Huaibao, Deraedt, William, van de Velde, Helgi, Arnulf, Bertrand
Publicado no Haematologica (2015)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase...

Por Zinzani, Pier Luigi, Khuageva, Nuriet K, Wang, Huaqing, Garicochea, Bernardo, Walewski, Jan, Van Hoof, Achiel, Soubeyran, Pierre, Caballero, Dolores, Buckstein, Rena, Esseltine, Dixie-Lee, Theocharous, Panteli, Enny, Christopher, Zhu, Eugene, Elsayed, Yusri A, Coiffier, Bertrand
Publicado em 2012

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-643...

Por LoRusso, Patricia M, Venkatakrishnan, Karthik, Ramanathan, Ramesh K, Sarantopoulos, John, Mulkerin, Daniel, Shibata, Stephen I, Hamilton, Anne, Dowlati, Afshin, Mani, Sridhar, Rudek, Michelle A, Takimoto, Chris H, Neuwirth, Rachel, Esseltine, Dixie-Lee, Ivy, Percy
Publicado em 2012

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Por Gupta, Neeraj, Goh, Yeow Tee, Min, Chang-Ki, Lee, Jae Hoon, Kim, Kihyun, Wong, Raymond S. M., Chim, Chor Sang, Hanley, Michael J., Yang, Huyuan, Venkatakrishnan, Karthik, Hui, Ai-Min, Esseltine, Dixie-Lee, Chng, Wee Joo
Publicado no J Hematol Oncol (2015)

Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution

Por Tang, Min, Zhao, Rui, van de Velde, Helgi, Tross, Jennifer G., Mitsiades, Constantine, Viselli, Suzanne, Neuwirth, Rachel, Esseltine, Dixie-Lee, Anderson, Kenneth, Ghobrial, Irene M., San Miguel, Jesús F., Richardson, Paul G., Tomasson, Michael H., Michor, Franziska
Publicado no Clin Cancer Res (2016)

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-do...

Por Mateos, María-Victoria, Bringhen, Sara, Richardson, Paul G., Lahuerta, Juan Jose, Larocca, Alessandra, Oriol, Albert, Boccadoro, Mario, García-Sanz, Ramón, Di Raimondo, Francesco, Esseltine, Dixie-Lee, van de Velde, Helgi, Desai, Avinash, Londhe, Anil, San Miguel, Jesús F., Palumbo, Antonio
Publicado em 2014

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Por Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Kukreti, Vishal, Vescio, Robert A., Pei, Lixia, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.
Publicado em 2014

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Por Lonial, Sagar, Waller, Edmund K., Richardson, Paul G., Jagannath, Sundar, Orlowski, Robert Z., Giver, Cynthia R., Jaye, David L., Francis, Dixil, Giusti, Sara, Torre, Claire, Barlogie, Bart, Berenson, James R., Singhal, Seema, Schenkein, David P., Esseltine, Dixie-Lee W., Anderson, Jessica, Xiao, Hugh, Heffner, Leonard T., Anderson, Kenneth C.
Publicado em 2005

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Por Richardson, Paul G., Weller, Edie, Jagannath, Sundar, Avigan, David E., Alsina, Melissa, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Ghobrial, Irene M., Doss, Deborah, Warren, Diane L., Lunde, Laura E., McKenney, Mary, Delaney, Carol, Mitsiades, Constantine S., Hideshima, Teru, Dalton, William, Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Publicado em 2009

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Por Lichter, David I., Danaee, Hadi, Pickard, Michael D., Tayber, Olga, Sintchak, Michael, Shi, Hongliang, Richardson, Paul G., Cavenagh, Jamie, Bladé, Joan, Façon, Thierry, Niesvizky, Ruben, Alsina, Melissa, Dalton, William, Sonneveld, Pieter, Lonial, Sagar, van de Velde, Helgi, Ricci, Deborah, Esseltine, Dixie-Lee, Trepicchio, William L., Mulligan, George, Anderson, Kenneth C.
Publicado em 2012

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

Por Richardson, Paul G., Xie, Wanling, Mitsiades, Constantine, Chanan-Khan, Asher A., Lonial, Sagar, Hassoun, Hani, Avigan, David E., Oaklander, Anne Louise, Kuter, David J., Wen, Patrick Y., Kesari, Santosh, Briemberg, Hannah R., Schlossman, Robert L., Munshi, Nikhil C., Heffner, L. Thompson, Doss, Deborah, Esseltine, Dixie-Lee, Weller, Edie, Anderson, Kenneth C., Amato, Anthony A.
Publicado em 2009

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Por Jakubowiak, Andrzej J., Griffith, Kent A., Reece, Donna E., Hofmeister, Craig C., Lonial, Sagar, Zimmerman, Todd M., Campagnaro, Erica L., Schlossman, Robert L., Laubach, Jacob P., Raje, Noopur S., Anderson, Tara, Mietzel, Melissa A., Harvey, Colleen K., Wear, Sandra M., Barrickman, Jennifer C., Tendler, Craig L., Esseltine, Dixie-Lee, Kelley, Susan L., Kaminski, Mark S., Anderson, Kenneth C., Richardson, Paul G.
Publicado em 2011

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Por Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Publicado em 2010

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Por Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, Anderson, Kenneth C.
Publicado em 2014

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Por Mulligan, George, Lichter, David I., Di Bacco, Alessandra, Blakemore, Stephen J., Berger, Allison, Koenig, Erik, Bernard, Hugues, Trepicchio, William, Li, Bin, Neuwirth, Rachel, Chattopadhyay, Nibedita, Bolen, Joseph B., Dorner, Andrew J., van de Velde, Helgi, Ricci, Deborah, Jagannath, Sundar, Berenson, James R., Richardson, Paul G., Stadtmauer, Edward A., Orlowski, Robert Z., Lonial, Sagar, Anderson, Kenneth C., Sonneveld, Pieter, San Miguel, Jesús F., Esseltine, Dixie-Lee, Schu, Matthew
Publicado em 2014

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Por Zhang, Xing-Ding, Baladandayuthapani, Veerabhadran, Lin, Heather, Mulligan, George, Li, Bin, Esseltine, Dixie-Lee W., Qi, Lin, Xu, Jianliang, Hunziker, Walter, Barlogie, Bart, Usmani, Saad Z., Zhang, Qing, Crowley, John, Hoering, Antje, Shah, Jatin J., Weber, Donna M., Manasanch, Elisabet E., Thomas, Sheeba K., Li, Bing-Zong, Wang, Hui-Han, Zhang, Jiexin, Kuiatse, Isere, Tang, Jin-Le, Wang, Hua, Jin, He, Yang, Jing, Milan, Enrico, Cenci, Simone, Ma, Wen-Cai, Wang, Zhi-Qiang, Davis, Richard Eric, Yang, Lin, Orlowski, Robert Z.
Publicado no Cancer Cell (2016)